{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:14:09Z","timestamp":1793315649720,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bioorg.2025.109305","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:39:11Z","timestamp":1764261551000},"page":"109305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives"],"prefix":"10.1016","volume":"168","author":[{"given":"Hamada S.","family":"Abulkhair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109305_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1684","article-title":"The nuclear export protein exportin-1 in solid malignant tumours: from biology to clinical trials","volume":"14","author":"Lai","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109305_bb0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 \u2014 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0015","author":"Muthusamy"},{"key":"10.1016\/j.bioorg.2025.109305_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/v10010048","article-title":"Verdinexor targeting of CRM1 is a promising therapeutic approach against RSV and influenza viruses","volume":"10","author":"Pickens","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.bioorg.2025.109305_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108073","article-title":"Targeting XPO1 for fighting relapsed\/refractory diseases: the research progress of XPO1 inhibitors","volume":"154","author":"Li","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nn.3953","article-title":"Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination","volume":"18","author":"Haines","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bioorg.2025.109305_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.675112","article-title":"The second-generation XPO1 inhibitor Eltanexor inhibits human cytomegalovirus (HCMV) replication and promotes type I interferon response","volume":"12","author":"Liao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0045","doi-asserted-by":"crossref","first-page":"29742","DOI":"10.1074\/jbc.272.47.29742","article-title":"Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins","volume":"272","author":"Kudo","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0050","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1021\/acs.jmedchem.0c00143","article-title":"Characterization of inhibition reveals distinctive properties for human and Saccharomyces cerevisiae CRM1","volume":"63","author":"Shaikhqasem","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbrc.2017.04.042","article-title":"Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1)","volume":"488","author":"Rahmani","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.109305_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00625","article-title":"Small molecule inhibitors of CRM1","volume":"11","author":"Ferreira","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11033-024-10169-5","article-title":"Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?","volume":"52","author":"Sokolova","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2025.109305_bb0075","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nature07975","article-title":"Structural basis for leucine-rich nuclear export signal recognition by CRM1","volume":"458","author":"Dong","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109305_bb0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0085","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/j.1600-0854.2008.00825.x","article-title":"Nuclear export signal consensus sequences defined using a localization-based yeast selection system","volume":"9","author":"Kosugi","year":"2008","journal-title":"Traffic"},{"key":"10.1016\/j.bioorg.2025.109305_bb0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semcancer.2014.04.012","article-title":"Targeting the \u03b2-catenin nuclear transport pathway in cancer","volume":"27","author":"Jamieson","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0095","series-title":"Crystal Structure of KPT-330 bound to CRM1 (537-DLTVK-541 to GLCEQ)","year":"2021"},{"key":"10.1016\/j.bioorg.2025.109305_bb0100","doi-asserted-by":"crossref","first-page":"15534","DOI":"10.1021\/acs.jmedchem.1c01145","article-title":"Chromosome region maintenance 1 (XPO1\/CRM1) as an anticancer target and discovery of its inhibitor","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0105","first-page":"1578","article-title":"The importin \u03b2 binding domain as a master regulator of nucleocytoplasmic transport","volume":"2011","author":"Lott","year":"1813","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.bioorg.2025.109305_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2015.06.001","article-title":"Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein","volume":"153","author":"Ishizawa","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109305_bb0115","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1021\/acs.jmedchem.4c00754","article-title":"Electrophile determines cellular phenotypes among XPO1-targeting small molecules","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0120","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A method for quantification of exportin-1 (XPO1) occupancy by selective inhibitor of nuclear export (SINE) compounds","volume":"7","author":"Crochiere","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.109305_bb0125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7150\/ijbs.66612","article-title":"Verdinexor, a selective inhibitor of nuclear Exportin 1, inhibits the proliferation and migration of esophageal Cancer via XPO1\/c-Myc\/FOSL1 Axis","volume":"18","author":"Ou","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2025.109305_bb0135","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.drudis.2020.06.014","article-title":"Exportin 1 inhibition as antiviral therapy","volume":"25","author":"Uddin","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109305_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105115","article-title":"Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo","volume":"192","author":"Kashyap","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bioorg.2025.109305_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a selective inhibitor of nuclear export, reduces respiratory syncytial virus replication in vitro","volume":"93","author":"Jorquera","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114053","article-title":"A review on the treatment of multiple myeloma with small molecular agents in the past five years","volume":"229","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116069","article-title":"Broad-spectrum antiviral strategy: host-targeting antivirals against emerging and re-emerging viruses","volume":"265","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yexcr.2005.08.022","article-title":"Identification of a nuclear export signal in the KSHV latent protein LANA2 mediating its export from the nucleus","volume":"311","author":"Mu\u00f1oz-Fontela","year":"2005","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bioorg.2025.109305_bb0165","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1074\/jbc.M408452200","article-title":"A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization","volume":"280","author":"Lin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11466","article-title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning","volume":"4","author":"K\u0131rl\u0131","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2025.109305_bb0175","doi-asserted-by":"crossref","first-page":"26895","DOI":"10.1039\/D2RA04015H","article-title":"In vitro and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-M pro inhibitors","volume":"12","author":"Aljuhani","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109305_bb0180","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1080\/07391102.2023.2167000","article-title":"The anticancer and EGFR-TK\/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro, and in silico mechanistic investigations","volume":"41","author":"Musa","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.109305_bb0185","doi-asserted-by":"crossref","DOI":"10.1080\/17568919.2025.2587561","article-title":"\u03b1-Glucosidase-targeting 1,2,4-triazole antidiabetic candidates: comparative analysis and future perspectives","author":"Abulkhair","year":"2025","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0190","doi-asserted-by":"crossref","first-page":"32778","DOI":"10.1039\/D5RA03702F","article-title":"A two-decade overview of oxadiazole derivatives as promising anticancer agents","volume":"15","author":"Salem","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109305_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400802","article-title":"The role of the sulfaguanidine molecular scaffold in drug design and development","volume":"358","author":"Abulkhair","year":"2025","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.109305_bb0200","first-page":"159","article-title":"Synthetic approaches, biological activity evaluations, and mechanistic investigations of sulfaguanidine-linked molecules","volume":"68","author":"Abulkhair","year":"2025","journal-title":"Egypt. J. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202500033","article-title":"A decade of research effort in synthesis, biological activity assessments, and mechanistic investigations of sulfamethazine-incorporating molecules","volume":"358","author":"Abulkhair","year":"2025","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.109305_bb0210","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11033-025-10497-0","article-title":"Targeting the undruggable MYC in cancer: the rationale of using XPO1 inhibitors","volume":"52","author":"Benetatos","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2025.109305_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100010","article-title":"A novel application of XPO1 inhibition for the treatment of myelofibrosis","volume":"1","author":"Metzger","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.bioorg.2025.109305_bb0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tips.2024.11.002","article-title":"Therapeutic targeting of exportin-1 beyond nuclear export","volume":"46","author":"Chen","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2025.109305_bb0225","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.109305_bb0230","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.clml.2023.07.013","article-title":"Real world efficacy and toxicity of Selinexor: importance of patient characteristics, dose intensity and post progression outcomes","volume":"23","author":"Kastritis","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bioorg.2025.109305_bb0235","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.1002\/ptr.7176","article-title":"Sulforaphane: a review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials","volume":"35","author":"Mangla","year":"2021","journal-title":"Phyther. Res."},{"key":"10.1016\/j.bioorg.2025.109305_bb0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cbi.2017.12.017","article-title":"Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through CRM1-mediated p62\/SQSTM1 accumulation and AMPK activation","volume":"281","author":"Wang","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2025.109305_bb0270","series-title":"Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY)","year":"2025"},{"key":"10.1016\/j.bioorg.2025.109305_bb0275","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I study of Selinexor, a selective inhibitor of nuclear export, in combination with Fludarabine and Cytarabine, in pediatric relapsed or refractory acute leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2024.134122","article-title":"Exploring triazole-based drugs: synthesis, application, FDA approvals, and clinical trial updates\u2013a comprehensive review","volume":"162","author":"Khan","year":"2024","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2025.109305_bb0285","series-title":"Selinexor (Xpovio), An XPO1 Inhibitor and a New Class of Therapeutics for Treating Multiple Myeloma","first-page":"253","author":"Mancuso","year":"2022"},{"key":"10.1016\/j.bioorg.2025.109305_bb0290","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.109305_bb0300","doi-asserted-by":"crossref","first-page":"159","DOI":"10.37871\/jbres1883","article-title":"Drug design strategies, modes of action, synthesis and industrial challenges behind Trifluoromethylated new chemical entities","volume":"5","author":"L. EPT, S. LMS","year":"2024","journal-title":"J. Biomed. Res. Environ. Sci."},{"key":"10.1016\/j.bioorg.2025.109305_bb0305","author":"Sandanayaka"},{"key":"10.1016\/j.bioorg.2025.109305_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118389","article-title":"A bottomless well: 1,2,4-Triazoles continue to inspire scientific researchers to develop more and more anticancer molecules","author":"Abulkhair","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1602911","article-title":"Selinexor in acute myeloid leukemia: therapeutic applications and current challenges","volume":"16","author":"Qie","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0320","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/sci.2019.02.03","article-title":"The past, present, and future of CRM1\/XPO1 inhibitors","volume":"6","author":"Wang","year":"2019","journal-title":"Stem Cell Investig."},{"key":"10.1016\/j.bioorg.2025.109305_bb0325","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0330","first-page":"1","article-title":"Drug delivery systems, CNS protection, and the blood brain barrier","volume":"2014","author":"Upadhyay","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bioorg.2025.109305_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200043","article-title":"In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals","volume":"13","author":"Widman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.109305_bb0340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10930-020-09884-2","article-title":"Covalent versus non-covalent enzyme inhibition: which route should we take? A Justification of the Good and Bad from Molecular Modelling Perspective","volume":"39","author":"Aljoundi","year":"2020","journal-title":"Protein J."},{"key":"10.1016\/j.bioorg.2025.109305_bb0345","doi-asserted-by":"crossref","first-page":"20595","DOI":"10.1021\/acs.jmedchem.4c02169","article-title":"Discovery of SZJK-0421: a novel potent, low toxicity, selective second generation of CRM1 inhibitor for the treatment of both hematological and solid tumors","volume":"67","author":"Miao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0350","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1021\/acs.jmedchem.3c01867","article-title":"Discovery of a hidden pocket beneath the NES groove by novel noncovalent CRM1 inhibitors","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0355","first-page":"70","article-title":"Crystal structure of human CRM1, covalently modified by 2-mercaptoethanol on Cys528, in complex with RanGTP, Acta Crystallogr","volume":"77","author":"Shaikhqasem","year":"2021","journal-title":"Sect. F Struct. Biol. Commun."},{"key":"10.1016\/j.bioorg.2025.109305_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114257","article-title":"Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells","volume":"235","author":"Qu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0365","article-title":"Discovery of novel XPO1 PROTAC degraders for the treatment of acute myeloid leukemia","volume":"283","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0370","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/ph14111131","article-title":"Inhibition of XPO-1 mediated nuclear export through the Michael-acceptor character of Chalcones","volume":"14","author":"Gargantilla","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109305_bb0375","doi-asserted-by":"crossref","first-page":"12141","DOI":"10.1021\/acs.jmedchem.5c00989","article-title":"XPO1-targeting selective inhibitors of transcriptional activation suppress graft-versus-host disease","volume":"68","author":"Shen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0380","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/molecules27082543","article-title":"Identification of novel covalent XPO1 inhibitors based on a hybrid virtual screening strategy","volume":"27","author":"Shen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109305_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112708","article-title":"A low toxic CRM1 degrader: synthesis and anti-proliferation on MGC803 and HGC27","volume":"206","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0395","article-title":"Chromenone derivatives as CRM1 inhibitors for targeting glioblastoma","author":"Princiotto","year":"2025","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bioorg.2025.109305_bb0400","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/tra.12802","article-title":"Discovery and biological evaluation of a small-molecule inhibitor of <scp>CRM1<\/scp> that suppresses the growth of triple-negative breast cancer cells","volume":"22","author":"Gao","year":"2021","journal-title":"Traffic"},{"key":"10.1016\/j.bioorg.2025.109305_bb0405","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80625","article-title":"Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK\/T cell lymphoma","volume":"12","author":"Liu","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2025.109305_bb0410","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noz170","article-title":"Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells","author":"Echizenya","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.bioorg.2025.109305_bb0415","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1021\/acs.jmedchem.0c01675","article-title":"Structure-guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1","volume":"64","author":"Lei","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0420","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/1439-7633(20010903)2:9<709::AID-CBIC709>3.0.CO;2-7","article-title":"The chemistry and biology of ratjadone","volume":"2","author":"Kalesse","year":"2001","journal-title":"Chembiochem"},{"key":"10.1016\/j.bioorg.2025.109305_bb0425","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1021\/acs.jmedchem.3c00549","article-title":"Discovery of Aminoratjadone derivatives as potent noncovalent CRM1 inhibitors","volume":"66","author":"Jian","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0430","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1039\/C8SC05542D","article-title":"The nuclear export inhibitor aminoratjadone is a potent effector in extracellular-targeted drug conjugates","volume":"10","author":"Klahn","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bioorg.2025.109305_bb0480","author":"Biovia"},{"key":"10.1016\/j.bioorg.2025.109305_bb0485","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bioorg.2017.04.014","article-title":"Rational design, synthesis, pharmacophore modeling, and docking studies for identification of novel potent DNA-PK inhibitors","volume":"72","author":"Ihmaid","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0435","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2021.01.008","article-title":"XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a","volume":"503","author":"Wang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.109305_bb0440","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/0008-5472.CAN-21-2964","article-title":"Inhibition of XPO1 sensitizes small cell lung Cancer to first- and second-line chemotherapy","volume":"82","author":"Quintanal-Villalonga","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109305_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117211","article-title":"Protein-protein interaction and interference of carcinogenesis by supramolecular modifications","volume":"81","author":"Saibu","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado6566","article-title":"The nuclear export protein XPO1 provides a peptide ligand for natural killer cells","volume":"10","author":"Blunt","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.109305_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.785635","article-title":"Selinexor enhances NK cell activation against malignant B cells via downregulation of HLA-E","volume":"11","author":"Fisher","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0460","doi-asserted-by":"crossref","first-page":"12231","DOI":"10.1038\/s41598-024-62852-z","article-title":"Adverse events reporting of XPO1 inhibitor - selinexor: a real-word analysis from FAERS database","volume":"14","author":"Liu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109305_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112708","article-title":"A low toxic CRM1 degrader: synthesis and anti-proliferation on MGC803 and HGC27","volume":"206","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109305_bb0465","author":"Austad"},{"key":"10.1016\/j.bioorg.2025.109305_bb0470","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40164-025-00655-2","article-title":"Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling","volume":"14","author":"Xiao","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.109305_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117465","article-title":"Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): emerging strategies for cancer therapy","volume":"289","author":"Hao","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501185X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501185X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:51:21Z","timestamp":1767693081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682501185X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":90,"alternative-id":["S004520682501185X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109305","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109305"}}